LearnGlossaryMarketStocksSuperinvestorsSign in

KYMR

Kymera Therapeutics, Inc.

Healthcare · $9.2B market cap

Verdict

We can't put a fair value on KYMR right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth14.4% a year✓
Sales growth0.3% a year✗
Free cash flow growth354.9% a year✓
Return on invested capital-27.5%✗

Follow KYMR

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 4, 2026: no open-market purchases and 3 sales worth $744K. Why purchases matter

Sales

Adams Brian

Chief Legal Officer · 2026-09-04

Sold

$251K

Adams Brian

Chief Legal Officer · 2026-09-04

Sold

$353K

Adams Brian

Chief Legal Officer · 2026-09-04

Sold

$140K

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works